过剩4
葡萄糖转运蛋白
胰岛素抵抗
胰岛素
染色体易位
葡萄糖摄取
糖尿病
敏化
体内
运输机
药理学
化学
内科学
生物
生物化学
医学
内分泌学
基因
生物技术
免疫学
作者
Terry C. Yin,Jonathan G. Van Vranken,Dhiraj Srivastava,Ayushi Mittal,Paul Buscaglia,Autumn E. Moore,Jissele A. Verdinez,Aschleigh E. Graham,Susan A. Walsh,Michael A. Acevedo,Robert J. Kerns,Nikolai O. Artemyev,Steven P. Gygi,Julien A. Sebag
标识
DOI:10.1016/j.chembiol.2023.06.012
摘要
Summary
Insulin resistance (IR) is the root cause of type II diabetes, yet no safe treatment is available to address it. Using a high throughput compatible assay that measures real-time translocation of the glucose transporter glucose transporter 4 (GLUT4), we identified small molecules that potentiate insulin action. In vivo, these insulin sensitizers improve insulin-stimulated GLUT4 translocation, glucose tolerance, and glucose uptake in a model of IR. Using proteomic and CRISPR-based approaches, we identified the targets of those compounds as Unc119 proteins and solved the structure of Unc119 bound to the insulin sensitizer. This study identifies compounds that have the potential to be developed into diabetes treatment and establishes Unc119 proteins as targets for improving insulin sensitivity.
科研通智能强力驱动
Strongly Powered by AbleSci AI